Since it has become difficult for many biopharmaceutical companies to raise money during the past year and a half, several firms have been forced to cut costs to make remaining cash balances last longer. Drug developers also have restructured and laid off employees as clinical trials and product launches failed to meet expectations, as was the case for FibroGen, Inc. and Amarin Corporation plc, which recently announced restructuring plans and job cuts.
Finance Watch: FibroGen, Amarin And Others Downsize To Survive
9 Meters’ Execs Resign After Bankruptcy, De-Listing
Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.
More from Strategy
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.